# VELCADE,Rituximab,Cyclophosphamide and Decadron

> **NCT00413959** · PHASE2 · TERMINATED · sponsor: **Oncology Specialists, S.C.** · enrollment: 12 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin
- Lymphoma, B-Cell

## Interventions

- **DRUG:** VELCADE®
- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Decadron

## Key facts

- **NCT ID:** NCT00413959
- **Lead sponsor:** Oncology Specialists, S.C.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-08
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2018-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00413959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00413959, "VELCADE,Rituximab,Cyclophosphamide and Decadron". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00413959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*